Michael Barbella, Managing Editor12.07.22
A study from XRHealth, a healthcare platform in the metaverse, shows the tremendous potential of virtual reality (VR) technologies as a treatment for upper limb dysfunction in multiple sclerosis patients.
XRHeatlth research indicates that VR technology not only is viable in treating upper limb dysfunction but is also safe for patients. Furthermore, patients' experiences during VR sessions were supervised and adjusted according to individual needs by physical therapists.
As new technologies such as VR and augmented reality (AR) are implemented more often in healthcare, companies arediscovering more ways to use these innovations to their advantage, concludes GlobalData.
“The COVID-19 pandemic triggered a shift to remote working that has boosted the adoption of VR by enterprises for training, collaboration, data visualization, and customer experience," said Kamilla Kan, a medical analyst at GlobalData. “Furthermore, more companies start to study ways to use VR in physiotherapy and treating various neurological disorders. As a result, the use of VR is expanding in the healthcare industry along with other new technologies, such as machine learning and artificial intelligence.”
GlobalData forecasts the global VR market to grow 13% annually to reach $28 billion in 2030—quadrupling its 2018 value of $7 million.
“VR therapy can become a more common way of therapy for neurological diseases in future due to its various benefits," Kan said. "VR is very likely to become one of the key technologies in healthcare and other industries, and the development of enterprise-grade metaverse platforms will further enhance its appeal.”
XRHeatlth research indicates that VR technology not only is viable in treating upper limb dysfunction but is also safe for patients. Furthermore, patients' experiences during VR sessions were supervised and adjusted according to individual needs by physical therapists.
As new technologies such as VR and augmented reality (AR) are implemented more often in healthcare, companies arediscovering more ways to use these innovations to their advantage, concludes GlobalData.
“The COVID-19 pandemic triggered a shift to remote working that has boosted the adoption of VR by enterprises for training, collaboration, data visualization, and customer experience," said Kamilla Kan, a medical analyst at GlobalData. “Furthermore, more companies start to study ways to use VR in physiotherapy and treating various neurological disorders. As a result, the use of VR is expanding in the healthcare industry along with other new technologies, such as machine learning and artificial intelligence.”
GlobalData forecasts the global VR market to grow 13% annually to reach $28 billion in 2030—quadrupling its 2018 value of $7 million.
“VR therapy can become a more common way of therapy for neurological diseases in future due to its various benefits," Kan said. "VR is very likely to become one of the key technologies in healthcare and other industries, and the development of enterprise-grade metaverse platforms will further enhance its appeal.”